caprotectin – Buhlmann Diagnostics Corp

Tag: caprotectin

Connect with BUHLMANN at DDW 2018

Digestive Diseases Week (DDW) 2018 BUHLMANN Diagnostics Corp  Booth: #2347 June 02-05, 2018 | Walter E. Washington Convention Center | Washington, DC Learn More Come by our booth to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio: Quantum Blue® platform offering rapid and quantitative results for fecal calprotectin, serum calprotectin, CRP and serum infliximab trough levels  (Additional trough level
Continue Reading

The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation: Abej, E. et al. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory BowelDisease Can J Gastroenterol Hepatol. 2016;2016:2483261. Epub 2016 Sep 28.DOI:10.1155/2016/2483261.  PMID: 27774443.  This Canadian study represents how FCAL testing is utilized in the field for monitoring disease activity in IBD.  The reference for the cut-off
Continue Reading

Are We Exposing Patients with a Mildly Elevated Faecal Calprotectin to Unnecessary Investigations?

BÜHLMANN fCAL®ELISA Citation: Seenan, JP, Thomson, Rankin K, Smith K, Gaya DR. Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations? Gastroenterology. 2014 Frontline Gastroenterol doi:10.1136/flgastro-2014-100467.

Highlight from this Publication:

“...we propose an alternative diagnostic approach of repeating the FC after 6-8 weeks in patients with values of 100-200 µg/g.”
Continue Reading

Monoclonal antibody testing for fecal calprotectin is superior to Polyclonal Testing of Fecal Calprotectin and Lactoferrin to Identify Organic Intestinal Disease in Patients with Adominal Discomfort

BÜHLMANN fCAL® ELISA Citation Burri E, Manz M., Rothen C, Rossi L,Beglinger C, Lehmann S. Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. Clinica Chimica Acta. 2013 Feb; 416: 41-47.  doi: 10.1016/j.cca.2012.11.008 Highlights from this Publication “…we demonstrated, that the
Continue Reading

Random Access Immuno Turbidimetric Faecal Calprotectin Assay

In autumn 2015 BÜHLMANN will launch a new generation of faecal calprotectin assay. The BÜHLMANN fCAL™turbo, the next step in automation of faecal calprotectin quantification used for Research Use Only. Fecal calprotectin (fCAL) is the most important marker in the study of gut inflammation. fCAL testing today demands for a raised level of lab resources including

Continue Reading